These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 22204765)

  • 1. Molecular alterations underlying eosinophilic and mast cell malignancies.
    Sadrzadeh H; Abdel-Wahab O; Fathi AT
    Discov Med; 2011 Dec; 12(67):481-93. PubMed ID: 22204765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders.
    Valent P
    Blood Rev; 2009 Jul; 23(4):157-65. PubMed ID: 19246139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
    Sotlar K
    Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders.
    Gotlib J; Akin C
    Semin Hematol; 2012 Apr; 49(2):128-37. PubMed ID: 22449623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mastocytosis: advances in diagnosis and treatment.
    Hungness SI; Akin C
    Curr Allergy Asthma Rep; 2007 Jul; 7(4):248-54. PubMed ID: 17547845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis, clinical features, and treatment advances in mastocytosis.
    Pardanani A; Akin C; Valent P
    Best Pract Res Clin Haematol; 2006; 19(3):595-615. PubMed ID: 16781490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms.
    Gotlib J
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):34-46. PubMed ID: 36485158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy.
    Gotlib J; Cross NC; Gilliland DG
    Best Pract Res Clin Haematol; 2006; 19(3):535-69. PubMed ID: 16781488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review.
    Savage N; George TI; Gotlib J
    Int J Lab Hematol; 2013 Oct; 35(5):491-500. PubMed ID: 23489324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the understanding of mastocytosis: the role of KIT mutations.
    Orfao A; Garcia-Montero AC; Sanchez L; Escribano L;
    Br J Haematol; 2007 Jul; 138(1):12-30. PubMed ID: 17555444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts.
    Valent P; Ghannadan M; Akin C; Krauth MT; Selzer E; Mayerhofer M; Sperr WR; Arock M; Samorapoompichit P; Horny HP; Metcalfe DD
    Eur J Clin Invest; 2004 Aug; 34 Suppl 2():41-52. PubMed ID: 15291805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mastocytosis.
    Metcalfe DD
    Novartis Found Symp; 2005; 271():232-42; discussion 242-9. PubMed ID: 16605139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis, progression patterns and prognostication in mastocytosis.
    Sperr WR; Valent P
    Expert Rev Hematol; 2012 Jun; 5(3):261-74. PubMed ID: 22780207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis.
    Gotlib J
    Curr Hematol Malig Rep; 2015 Dec; 10(4):351-61. PubMed ID: 26404639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clonal eosinophilia revealed by recurrent Staphylococcus aureus infection].
    Vandenbos F; Figueredo M; Dumon-Gubeno MC; Nicolle I; Tarhini A; Medioni LD; Naman H; Mouroux J
    Rev Pneumol Clin; 2011 Jun; 67(3):167-9. PubMed ID: 21665081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eosinophilic myeloid disorders.
    Noel P
    Semin Hematol; 2012 Apr; 49(2):120-7. PubMed ID: 22449622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors.
    Pittoni P; Piconese S; Tripodo C; Colombo MP
    Oncogene; 2011 Feb; 30(7):757-69. PubMed ID: 21057534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KIT and mastocytosis.
    Lim KH; Pardanani A; Tefferi A
    Acta Haematol; 2008; 119(4):194-8. PubMed ID: 18566536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mastocytosis - an update.
    Amon U; Hartmann K; Horny HP; Nowak A
    J Dtsch Dermatol Ges; 2010 Sep; 8(9):695-711; quiz 712. PubMed ID: 20678151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the lineage relationship between mast cells and basophils using the c-kit D816V mutation as a biologic signature.
    Kocabas CN; Yavuz AS; Lipsky PE; Metcalfe DD; Akin C
    J Allergy Clin Immunol; 2005 Jun; 115(6):1155-61. PubMed ID: 15940128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.